MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ejhf.2894

Медицинская библиотека · European journal of heart failure · 2023

Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.

Anker Stefan D, Usman Muhammad Shariq, Anker Markus S, Butler Javed, Böhm Michael, Abraham William T, Adamo Marianna, Chopra Vijay K, Cicoira Mariantonietta, Cosentino Francesco, Filippatos Gerasimos, Jankowska Ewa A, Lund Lars H, Moura Brenda, Mullens Wilfried, Pieske Burkert, Ponikowski Piotr, Gonzalez-Juanatey Jose R, Rakisheva Amina, Savarese Gianluigi, Seferovic Petar, Teerlink John R, Tschöpe Carsten, Volterrani Maurizio, von Haehling Stephan, Zhang Jian, Zhang Yuhui, Bauersachs Johann, Landmesser Ulf, Zieroth Shelley, Tsioufis Konstantinos, Bayes-Genis Antoni, Chioncel Ovidiu, Andreotti Felicita, Agabiti-Rosei Enrico, Merino Jose L, Metra Marco, Coats Andrew J S, Rosano Giuseppe M C

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation of various combinations of cardiovascular, metabolic, pulmonary, renal, and geriatric conditions. Thus, in addition to treatment with sodium-glucose cotransporter 2 inhibitors in all patients, the most effective method of improving clinical outcomes may be therapy tailored to each patient's clinical profile. To better outline a phenotype-based approach for the treatment of HFpEF, in this joint position paper, the Heart Failure Association of the European Society of Cardiology, the European Heart Rhythm Association and the European Hypertension Society, have developed an algorithm to identify the most common HFpEF phenotypes and identify the evidence-based treatment strategy for each, while taking into account the complexities of multiple comorbidities and polypharmacy.

Для цитирования: Anker Stefan D, Usman Muhammad Shariq, Anker Markus S, Butler Javed, Böhm Michael, Abraham William T, Adamo Marianna, Chopra Vijay K, Cicoira Mariantonietta, Cosentino Francesco, Filippatos Gerasimos, Jankowska Ewa A, Lund Lars H, Moura Brenda, Mullens Wilfried, Pieske Burkert, Ponikowski Piotr, Gonzalez-Juanatey Jose R, Rakisheva Amina, Savarese Gianluigi, Seferovic Petar, Teerlink John R, Tschöpe Carsten, Volterrani Maurizio, von Haehling Stephan, Zhang Jian, Zhang Yuhui, Bauersachs Johann, Landmesser Ulf, Zieroth Shelley, Tsioufis Konstantinos, Bayes-Genis Antoni, Chioncel Ovidiu, Andreotti Felicita, Agabiti-Rosei Enrico, Merino Jose L, Metra Marco, Coats Andrew J S, Rosano Giuseppe M C. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.. European journal of heart failure. 2023. DOI: 10.1002/ejhf.2894.

Предметные рубрики MeSH

HumansHeart FailureStroke VolumeHypertensionCardiologyPhenotypeDecision MakingVentricular Function, Left
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.